Login to Your Account

Clinic Roundup

Wednesday, June 6, 2012

• Aeterna Zentaris Inc., of Quebec City, said Phase I results of its oral cancer compound, perifosine, in multiple myeloma, were published in the online issue of the British Journal of Haematology. The article reviews the safety profile and clinical activity of the PI3K/Akt pathway inhibitor when combined with Revlimid (lenalidomide, Celgene Corp.) and dexamethasone in relapsed and relapsed/refractory multiple myeloma. Perifosine is partnered with Keryx Biopharmaceuticals Inc., of New York.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription